
USD $861.00
Olumiant (Baricitinib) is an oral medication primarily used for the treatment of moderate to severe rheumatoid arthritis in adults. It is a Janus kinase (JAK) inhibitor that works by interfering with the inflammatory process, thereby reducing symptoms and improving physical function.
Olumiant is indicated for the treatment of:
The recommended dosage of Olumiant is determined by the prescribing physician based on the patient's condition and response to treatment. It is usually taken once daily, with or without food. It is important to follow the prescribed dosage and not to take more than directed.
Baricitinib selectively inhibits JAK1 and JAK2 enzymes, which play a crucial role in the signaling of various cytokines involved in the inflammatory response. By blocking these enzymes, Olumiant helps to reduce inflammation and alleviate symptoms associated with rheumatoid arthritis.
Common side effects of Olumiant may include:
Serious side effects can occur, including serious infections, blood clots, and changes in blood cell counts. Patients should be monitored regularly for these potential risks.
Before starting Olumiant, inform your healthcare provider about any medical history, especially:
It is not recommended for use in patients who are pregnant, breastfeeding, or have active infections.
Olumiant (Baricitinib) offers a targeted approach for managing rheumatoid arthritis, providing patients with an option to improve their quality of life. Always consult with a healthcare professional for personalized medical advice and treatment plans.